Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28718097 | 0.84 | HPGD (0.55) | ALDH1A1GAADRD1MAPK1L3MBTL1 | |
| SCHEMBL4076975 | 0.81 | ATP4A (0.38) | ALDH1A1GAADRD1HPGDSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL28132731 | 0.81 | ALDH1A1 (0.38) | ALDH1A1GAADRD1MAPK1L3MBTL1 | |
| SCHEMBL4079859 | 0.81 | ATP4A (0.40) | ALDH1A1GAADRD1MAPK1L3MBTL1 | |
| SCHEMBL4072811 | 0.81 | ALDH1A1 (0.38) | ALDH1A1GAADRD1MAPK1L3MBTL1 | |
| SCHEMBL4082143 | 0.81 | RUNX1 (0.35) | ALDH1A1GAADRD1MAPK1L3MBTL1 | |
| SCHEMBL24344996 | 0.79 | HCRTR1 (0.39) | ALDH1A1DRD1HPGDSMN1; SMN2 | |
| SCHEMBL27476345 | 0.79 | HPGD (0.35) | ALDH1A1GAAMAPK1L3MBTL1HPGD | |
| SCHEMBL4080571 | 0.79 | MAOA (0.42) | ALDH1A1GAADRD1CCR1CCR5 | |
| SCHEMBL6792963 | 0.79 | NOS3 (0.48) | ALDH1A1GAACYP1A2CYP2C19CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4482579-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LHOTSE BIO INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12428375-B2 | Compounds and compositions for treating conditions associated with LPA receptor activity | LHOTSE BIO, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| EP-4482579-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | Lhotse Bio, Inc. (US) | 2025-01-01 | — | — | EP | disclosed |
| CN-119110795-A | Compounds and compositions for treating conditions associated with LPA receptor activity | 罗特斯生物公司 | 2024-12-10 | — | — | CN | disclosed |
| US-20240376054-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LHOTSE BIO, INC. | 2024-11-14 | — | — | US | disclosed |
| US-11884627-B2 | Compounds and compositions for treating conditions associated with LPA receptor activity | LHOTSE BIO, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-20230322675-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LHOTSE BIO, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322675-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LHOTSE BIO, INC. | 2023-10-12 | — | — | US | disclosed |
| WO-2023160672-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LHOTSE BIO , INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| EP-3300500-B9 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2021-01-13 | — | — | EP | disclosed |
| WO-2015199136-A1 | NOVEL PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING SAME, ESPECIALLY AGENT FOR PREVENTION AND/OR TREATMENT OF TUMORS ETC BASED ON NAE INHIBITORY EFFECT | 大鵬薬品工業株式会社 | 2015-12-30 | — | — | WO | disclosed |
| US-7572918-B2 | Prepared in high yield and high purity without the need for isolation of intermediates and chromatographic purification; useful as muscarinic receptor antagonists; 4-{N-[7-(3-(S)-1-carbamoyl-1,1-diphenylmethyl)-pyrrolidin-1-yl)-hept-1-yl]-N-(isopropyl)amino}-1-(4-methoxypyrid-3-ylmethyl)-piperidine | THERAVANCE, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-20080091034-A1 | Substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds | THERAVANCE, INC. | 2008-04-17 | — | — | US | disclosed |
| US-7285564-B2 | Substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds | THERAVANCE, INC. (US) | 2007-10-23 | — | — | US | disclosed |
| EP-1556372-B1 | SUBSTITUTED 4-AMINO-1-(PYRIDYLMETHYL) PIPERIDINE AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE INC (US) | 2007-05-30 | — | — | EP | disclosed |
| US-20060094878-A1 | Process for preparing substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds | THERAVANCE, INC. | 2006-05-04 | — | — | US | disclosed |
| US-20040116480-A1 | Oxime ether compound and agricultural or horticultural bactericide | NIPPON SODA CO., LTD. (JP) | 2004-06-17 | — | — | US | disclosed |
| EP-1362850-A1 | OXIME ETHER COMPOUND AND AGRICULTURAL OR HORTICULTURAL BACTERICIDE | NIPPON SODA CO., LTD. (JP) | 2003-11-19 | — | — | EP | disclosed |
| CN-1011969-B | Benzimidazole derivatives and their preparation | BYK GULDEN LOMBERG CHEM FAB (DE) | 1991-03-13 | — | — | CN | disclosed |
| CN-85104684-A | The dialkoxy pyridine, their preparation method, purposes and contain their medicine | — | 1986-12-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322675-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LPAR2, LPAR1, LPAR6 | ALDH1A1 1863/4885GAA 310/4885DRD1 4808/4885 |
| US-20060094878-A1 | Process for preparing substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds | CHRM4, CHRM3, CHRM1 | ALDH1A1 1356/4885GAA 3358/4885DRD1 190/4885 |
| US-11884627-B2 | Compounds and compositions for treating conditions associated with LPA receptor activity | LPAR2, LPAR1, LPAR6 | ALDH1A1 1863/4885GAA 310/4885DRD1 4808/4885 |
| US-20080091034-A1 | Substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds | CHRM5, CHRM1, CHRM3 | ALDH1A1 807/4885GAA 4256/4885DRD1 212/4885 |
| US-20240376054-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LPAR2, LPAR1, LPAR6 | ALDH1A1 1863/4885GAA 310/4885DRD1 4808/4885 |
| US-12428375-B2 | Compounds and compositions for treating conditions associated with LPA receptor activity | LPAR2, LPAR1, LPAR6 | ALDH1A1 1863/4885GAA 310/4885DRD1 4808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.